Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway - PubMed (original) (raw)
. 2002 Aug 16;277(33):29936-44.
doi: 10.1074/jbc.M204733200. Epub 2002 Jun 6.
Affiliations
- PMID: 12052835
- DOI: 10.1074/jbc.M204733200
Free article
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway
Jennifer S Isaacs et al. J Biol Chem. 2002.
Free article
Abstract
HIF-1 alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1 alpha protein levels, efficiently targets HIF-1 alpha for rapid proteasome-dependent degradation under normoxia, HIF-1 alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1 alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1 alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1 alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1 alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1 alpha point mutations that block VHL association did not protect HIF-1 alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1 alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1 alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1 alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1 alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.
Similar articles
- The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism.
Tang TT, Lasky LA. Tang TT, et al. J Biol Chem. 2003 Aug 8;278(32):30125-35. doi: 10.1074/jbc.M302042200. Epub 2003 May 21. J Biol Chem. 2003. PMID: 12761217 - Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K, Makino Y, Pereira T, Poellinger L. Tanimoto K, et al. EMBO J. 2000 Aug 15;19(16):4298-309. doi: 10.1093/emboj/19.16.4298. EMBO J. 2000. PMID: 10944113 Free PMC article. - Regulation of STRA13 by the von Hippel-Lindau tumor suppressor protein, hypoxia, and the UBC9/ubiquitin proteasome degradation pathway.
Ivanova AV, Ivanov SV, Danilkovitch-Miagkova A, Lerman MI. Ivanova AV, et al. J Biol Chem. 2001 May 4;276(18):15306-15. doi: 10.1074/jbc.M010516200. Epub 2001 Feb 6. J Biol Chem. 2001. PMID: 11278694 - Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ. Mole DR, et al. IUBMB Life. 2001 Jul;52(1-2):43-7. doi: 10.1080/15216540252774757. IUBMB Life. 2001. PMID: 11795592 Review. - Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA, Ohh M. Maynard MA, et al. Am J Nephrol. 2004 Jan-Feb;24(1):1-13. doi: 10.1159/000075346. Epub 2003 Dec 3. Am J Nephrol. 2004. PMID: 14654728 Review.
Cited by
- Functional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase.
Liu Q, Geng H, Xue C, Beer TM, Qian DZ. Liu Q, et al. Biochim Biophys Acta. 2015 May;1853(5):881-91. doi: 10.1016/j.bbamcr.2015.01.011. Epub 2015 Jan 28. Biochim Biophys Acta. 2015. PMID: 25637186 Free PMC article. - Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
Nomura T, Yamasaki M, Hirai K, Inoue T, Sato R, Matsuura K, Moriyama M, Sato F, Mimata H. Nomura T, et al. Mol Cancer. 2013 Apr 8;12:27. doi: 10.1186/1476-4598-12-27. Mol Cancer. 2013. PMID: 23566222 Free PMC article. - Hypoxia/HIF Modulates Immune Responses.
Chen Y, Gaber T. Chen Y, et al. Biomedicines. 2021 Mar 5;9(3):260. doi: 10.3390/biomedicines9030260. Biomedicines. 2021. PMID: 33808042 Free PMC article. Review. - Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation.
Bohonowych JE, Peng S, Gopal U, Hance MW, Wing SB, Argraves KM, Lundgren K, Isaacs JS. Bohonowych JE, et al. BMC Cancer. 2011 Dec 15;11:520. doi: 10.1186/1471-2407-11-520. BMC Cancer. 2011. PMID: 22172030 Free PMC article. - Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1.
To KK, Huang LE. To KK, et al. J Biol Chem. 2005 Nov 11;280(45):38102-7. doi: 10.1074/jbc.M504342200. Epub 2005 Sep 12. J Biol Chem. 2005. PMID: 16157596 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources